Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors

NCT04767906 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
16
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

University of Leipzig